Fetal and Neonatal Alloimmune Thrombocytopenia
Oncology·MeSH: Thrombocytopenia, Neonatal Alloimmune
Prevalence
30.0 / 100K
2 drugs in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Fetal and Neonatal Alloimmune Thrombocytopenia?
BioSniper tracks 2 drugs in development for Fetal and Neonatal Alloimmune Thrombocytopenia across 1 company.
How many clinical trials target Fetal and Neonatal Alloimmune Thrombocytopenia?
There are 2 clinical trials targeting Fetal and Neonatal Alloimmune Thrombocytopenia tracked by BioSniper.
What is the prevalence of Fetal and Neonatal Alloimmune Thrombocytopenia?
The estimated prevalence of Fetal and Neonatal Alloimmune Thrombocytopenia is approximately 30.0 per 100,000 population.
Deep-dive into Fetal and Neonatal Alloimmune Thrombocytopenia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis